Iferanserin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Iferanserin
Iferanserin.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC23H28N2O
Molar mass348.481 g/mol
3D model (JSmol)

Iferanserin (INN; VEN-309) is a drug which acts as a selective 5-HT2A receptor antagonist.[1] It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials.[1]

References[edit]

  1. ^ a b Herold A, Dietrich J, Aitchison R (February 2012). "Intra-anal Iferanserin 10 mg BID for hemorrhoid disease: a prospective, randomized, double-blind, placebo-controlled trial". Clinical Therapeutics. 34 (2): 329–40. doi:10.1016/j.clinthera.2011.12.012. PMID 22244049.